Previous view $160M-$180M. Raises FY25 Cell Engineering revenue view to $117M-$137M from $110M-$130M. Backs FY25 Bisecurity revenue view at least $50M. Ginkgo updated its previously issued guidance solely to reflect the impact of the previously mentioned $7M non-cash deferred revenue release in Q1.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNA:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue